Clik here to view.
Takeda Shareholders Approve Resolutions Related to the Proposed Acquisition...
OSAKA, Japan NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH...
View ArticleClik here to view.
武田薬品、プロテアソーム阻害剤による維持療法を評価する初のピボタル第3相プラセボ対照試験TOURMALINE-MM3の良好データを発表へ
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
武田股东批准拟收购Shire plc相关决议
日本大阪 (美国商业资讯)–如在任何司法管辖区内直接或间接发布、出版或分发全部或部分内容构成违反该司法管辖区有关法律的行为，则不得在此等司法管辖区实施该行为。 武田药品工业株式会社(TSE: 4502)（“武田”）今天宣布了其特别股东大会（“EGM”）上关于建议的收购Shire plc（“Shire”）之交易（“收购”）的股东投票结果。...
View ArticleClik here to view.
武田の株主がシャイアー買収案に関連した決議事項を承認
大阪 （ビジネスワイヤ） — 本プレスリリースは、その発表、公表または配布が適用法違反となる法域において、全体または一部を問わず、直接または間接的に発表、公表または配布してはなりません。 武田薬品工業株式会社（東証：4502）（以下「武田」）は本日、シャイアーの買収案（以下「本件買収」）に関する臨時株主総会での株主決議の結果を発表しました。...
View ArticleClik here to view.
Seattle Genetics和武田呈报 ADCETRIS® (Brentuximab...
华盛顿州博瑟尔、马萨诸塞州剑桥和日本大阪 (美国商业资讯) — Seattle Genetics, Inc. (Nasdaq:SGEN)和武田药品工业株式会社(TSE:4502)宣布，3期ECHELON-2临床试验数据将于今天在美国血液学会(ASH)第60届年会上进行口述呈报。该数据显示，ADCETRIS (brentuximab...
View ArticleClik here to view.
Aptorum Group Limited Announces Pricing of Initial Public Offering
HONG KONG Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic...
View ArticleClik here to view.
Samsung Bioepis Announces Results of Additional One-Year Follow-Up Study...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced the results of an additional one-year follow-up study comparing event-free survival (EFS) of SB3, a biosimilar candidate referencing...
View ArticleClik here to view.
シアトル・ジェネティクスと武田薬品がCD30発現末梢性T細胞リンパ腫のフロントライン治療でアドセトリス（ブレンツキシマブ・ベドチン）を検討する第3相ECH...
米ワシントン州ボセル & マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Takeda and the New York Academy of Sciences Announce 2019 Innovators in...
NEW YORK & OSAKA, Japan Takeda Pharmaceutical Company Limited, (“Takeda”) (TSE:4502) and the New York Academy of Sciences announced today the Winners of the second annual Innovators in Science...
View ArticleClik here to view.
武田薬品とニューヨーク科学アカデミーによる”2019 Innovators in Science Award”の受賞者発表について
NEW YORK & OSAKA, Japan （ビジネスワイヤ） — 武田薬品工業株式会社（本社：大阪市中央区、以下「武田薬品」）とニューヨーク科学アカデミー（The New York Academy of Sciences、本部：米国ニューヨーク州ニューヨーク、以下「NYAS」）は、このたび、今年で2回目となる学術賞“Innovators in Science...
View ArticleClik here to view.
武田和纽约科学院宣布2019年度科学创新者奖获奖人
纽约市和日本大阪 (美国商业资讯) — 武田药品工业株式会社（Takeda Pharmaceutical Company Limited，简称“武田”）(TSE:4502)和纽约科学院今天宣布了每年一次的科学创新者奖第二年的获奖人，以表彰他们在再生医学领域的承诺和卓越贡献。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...
View ArticleClik here to view.
Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a...
INCHEON, South Korea & JERUSALEM Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has...
View ArticleClik here to view.
Aptorum Group Limited Announces Closing of Initial Public Offering
HONG KONG Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic...
View ArticleClik here to view.
Aptorum Group [APM] to Ring the NASDAQ Stock Market Closing Bell in...
HONG KONG Aptorum Group Limited (“APM”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic...
View ArticleClik here to view.
武田薬品、未治療のCD30陽性ステージ4ホジキンリンパ腫成人患者を治療するためのアドセトリス（ブレンツキシマブ・ベドチン）とAVDの併用に関するCHMPの...
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社(TSE:...
View ArticleClik here to view.
武田获得CHMP肯定意见，接纳ADCETRIS® (brentuximab vedotin)联合AVD用于治疗既往未曾治疗的CD30+...
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，欧洲药品管理局(EMA)人用药品委员会(CHMP)采纳了一项肯定意见，延长ADCETRIS (brentuximab vedotin)的上市许可，并推荐核准该药联合AVD用于既往未曾治疗的CD30+...
View ArticleClik here to view.
Spirita Oncology Initiated Global Clinical Development of E6201 in...
BOSTON Spirita Oncology, LLC, announced that it has entered into a sublicense agreement with JS Innopharm (Shanghai) Ltd. to initiate global clinical development of E6201, a potent MEK1 inhibitor...
View ArticleClik here to view.
Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES...
TOKYO & NEW YORK Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating...
View ArticleClik here to view.
1ST Biotherapeutics and twoXAR Form Co-Development Collaboration to Discover...
SEONGNAM, South Korea & MOUNTAIN VIEW, Calif. 1ST Biotherapeutics, Inc., a preclinical-stage biotechnology company focused on neurodegenerative diseases, immuno-oncology, and orphan diseases,...
View Article